Breast surgery and systemic treatment continuation for patients with de novo metastatic breast cancer and locoregional oligoprogression: a cohort study
This study suggests that selected patients with de novo mBC and locoregional oligoprogression can benefit from breast surgery while maintaining the same systemic treatment, particularly in the setting of HER2-positive disease or a pre-oligoprogression PFS >1 year.
Authors
- C. Sangalli
- Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
- Dario Trapani (ORCID: https://orcid.org/0000-0003-1672-9560)
- Elisabetta Munzone (ORCID: https://orcid.org/0000-0003-3371-3878)
- Nadia Bianco (ORCID: https://orcid.org/0000-0001-5765-7765)
- S. Di Bella (ORCID: https://orcid.org/0009-0003-0292-4135)
- P. Veronesi
- I. Minchella
- M Colleoni
- Angela Sciandivasci
- Carmine Valenza (ORCID: https://orcid.org/0000-0003-1150-0345)
- Monica Milano (ORCID: https://orcid.org/0000-0003-0983-1604)
- M. Intra
- V. Galimberti
Institutions
- University of Milan (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- European Institute of Oncology (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105920
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00